U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07886554) titled 'LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)' on Oct. 09.
Brief Summary: A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH)
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Sarcoidosis Associated Pulmonary Hypertension
Intervention:
DRUG: Placebo
Matching placebo administered via dry powder inhalation
DRUG: LAM-001
LAM-001 administered via dry powder inhaler
DRUG: LAM-001
LAM-001 administered via dry powder inhal...